GLUCAGON
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
GLUCAGON by Eli Lilly and Company is clinical pharmacology glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. First approved in 1960.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glucagon is a small-molecule injectable hormone that treats severe hypoglycemia in pediatric patients by stimulating glycogen breakdown and glucose release from the liver. It works by activating glucagon receptors in hepatic tissue and also produces extrahepatic effects including smooth muscle relaxation in the GI tract. This classic emergency treatment addresses life-threatening low blood sugar episodes when oral glucose cannot be administered.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), likely requiring defensive positioning and possible team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose. Glucagon administered through a parenteral route relaxes smooth muscle of the stomach, duodenum, small bowel, and…
Indications
Worked on GLUCAGON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.